TransCode Therapeutics, Inc.
RNAZHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeTransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The $2.2M market capitalization puts RNAZ squarely in micro-cap range for its industry. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Market Cap
$2.2M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-3.43
EPS (TTM)
$-48.28
EPS (Fwd)
$-0.60
ROE
-59.3%
ROA
-19.9%
Cash
$8.4M
Total Debt
$652,411
Free CF
-$13.8M
52W Change
-80.2%
Annual Financials
Cash vs Debt
Where RNAZ stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RNAZ finished 71.81% below its 150-day moving average ($7.13) and 73.24% below its 200-day moving average ($7.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RNAZ overbought or oversold?
At the September 3, 2026 close, RNAZ's RSI(14) was 4.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $8.4M in cash comfortably exceeding the $652K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$13.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -59.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, RNAZ has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for TransCode Therapeutics, Inc. and its sector.